Dario Amodei is not known for being the most active on X but yesterday on August 16, his two-part reply to investor Gavin Baker, CIO of Atreides Management brought over 14 million views as of this writing and even got Elon Musk to react to the thread. The second part of the reply highlighted the prediction he is best known for in that AI will make it possible to cure most human diseases in around five to ten years. He acknowledged how that reads by saying that the thought of it likely sounds crazy to ordinary people and to biologists as well.
2/2 Second, on the messaging around AI. I do not agree that my messaging has been disproportionately negative. In fact it has been about equally balanced between risks and benefits: I’ve written one major essay about each, and even in interviews where I discuss the risks, I…
— Dario Amodei (@DarioAmodei) August 15, 2026
Why Amodei Was Replying At All
Baker had spent part of an An-In podcast segment on Anthropic, stating that he had been told Amodei privately brought up the possibility that his company could be the only private company left in the world, with governments running everything else. Baker followed it up on X with a broader complaint. He argued that Amodei has lost the regulation argument and that he should be a more positive advocate for the industry he leads.
Amodei disagreed on the framing. His two major essays split evenly between risk and benefit, he argued and that clips taken from interviews get a lot more traction on social media when they sound bleak. Machines of Loving Grace, the 15,000-word essay he published back in October 2024, was the benefit half. Most of the essay argues that AI has the capability to compress 50 to 100 years of biological progress into 5 to 10.
The Admission Attached to the Forecast
The more useful part of the post was not the prediction. It was what Amodei conceded around it.
He called the sharpest criticism of AI companies, his own included, the fact that they have not delivered on what they promised the world. He put that squarely on the industry rather than on its critics. He also rejected the idea of fixing public sentiment with a marketing push, saying that promising to cure cancer now reads as cliché and mostly comes across as deceptive. Actually curing it is the only thing that works.
Then came the timeline nobody asked for. Anthropic is accelerating its work in biology and medicine, and Amodei said he expects major results in the coming years with “some early glimmers in the coming months.”
Anthropic Has Been Buying Into the Thesis for Months
The claim is not floating free. Anthropic launched Claude for Life Sciences in October last year, announced research partnerships with the Allen Institute and the Howard Hughes Medical Institute on February 2, and reportedly acquired stealth biotech startup Coefficient Bio in a $400 million stock deal. Coefficient’s two founders came out of computational drug discovery at Genentech’s Prescient Design, and the roughly ten-person team is joining Anthropic’s health and life sciences group.
A Decade-Long Call Now Has a Near-Term Checkpoint
Ten-year predictions are cheap because nobody collects on them. Amodei just attached a shorter one to his.
Glimmers in months is a claim that can be checked, and quickly. He said that when Anthropic accomplishes something real the world will hear about it as loudly as possible, and that until then he does not want to make empty promises. That is a firmer commitment than most AI executives put in writing, and the timing is not incidental. Anthropic filed confidentially with the SEC in June, and its backers are already modelling a $2 trillion valuation for an October listing. The early glimmers would land right around the same window.
